Profile of aminopyridines for Lambert–Eaton myasthenic syndrome

References

• Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol. 1956;187:612–613.
   Web of Science ®Google Scholar
• Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971;183:183–199.
   PubMed Web of Science ®Google Scholar
• O’Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577–596.
   PubMed Web of Science ®Google Scholar
• Wirtz PW, van Dijk JG, van Doorn PA, et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in The Netherlands. Neurology. 2004;63:397–398.
   PubMed Web of Science ®Google Scholar
• Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981;2(8240):224–226.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–1474.
   PubMed Web of Science ®Google Scholar
• Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85–87.
   PubMed Web of Science ®Google Scholar
• Lambert EH. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci. 1966;135:367–384.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Kim KW. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology. 1973;23:1084–1090.
   PubMed Web of Science ®Google Scholar
• Blumhardt LD, Joekes AM, Marshall J, Philalithis PE. Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome. Br Med J. 1977;1(6066):946–947.
   Google Scholar
• Oh SJ, Kim DS, Head TC, Claussen GC. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1997;20:1146–1152.
   PubMed Web of Science ®Google Scholar
• Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res. 1978;153:307–318.
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. 4-Aminopyridine – a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry. 1977;40:1109–1112.
   PubMed Web of Science ®Google Scholar
• Agoston S, van Weerden T, Westra P, Broekert A. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br J Anaesth. 1978;50:383–385.
   PubMed Web of Science ®Google Scholar
• Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology. 1981;31:265–271.
   PubMed Web of Science ®Google Scholar
• Lemeignan M. Pharmacological approach to the study of convulsive action mechanism of amino-4 pyridine. Therapie. 1971;26:927–940. French.
   Web of Science ®Google Scholar
• European Medicines Agency. Summary of Product Characteristics. Firdapse® (amifampridine). Date of Preparation of Text Jan 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001032/WC500069915.pdf. Accessed December 9, 2013.
   Google Scholar
• Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol. 1980;61:25–34.
   PubMed Web of Science ®Google Scholar
• Lechat P, Deysson G, Lemeignan M, Adolphe M. [Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture)]. Ann Pharm Fr. 1968;26:345–349. French.
   PubMed Web of Science ®Google Scholar
• Lemeignan M, Millart H, Letteron N, et al. The ability of 4-aminopyridine and 3,4-diaminopyridine to cross the blood-brain barrier can account for their difference in toxicity. In: Lechat P, Thesleff S, Bowman WC, editors. Aminopyridines and Similarly Acting Drugs: Effects on Nerves, Muscles And Synapses. Advances in the Biosciences. Oxford: Pergamon Press; 1982;35:222–229.
   Google Scholar
• Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry. 1983;46:684–685.
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand. 1993;88:136–140.
   PubMed Web of Science ®Google Scholar
• AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24:1236–1238.
   Web of Science ®Google Scholar
• AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2001;24:1239–1247.
   Web of Science ®Google Scholar
• Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32:515–520.
   PubMed Web of Science ®Google Scholar
• Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983;33:1316–1321.
   PubMed Web of Science ®Google Scholar
• Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719–724.
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–772.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Chichester: John Wiley & Sons; 2009. Chapter 8.
   Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–1571.
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, cross-over study. Clin Pharmacol Ther. 2009;86:44–48.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40:795–800.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Chichester: John Wiley & Sons; 2009. Chapter 9.
   Google Scholar
• Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54:603–607.
   PubMed Web of Science ®Google Scholar
• Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol. 1995;33:249–251.
   PubMed Web of Science ®Google Scholar
• Hawkes N, Cohen D. What makes an orphan drug? BMJ. 2010;341:c6459.
   Google Scholar
• Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J. 2004;12:183–200.
   PubMedGoogle Scholar
• European Medicines Agency. Orphan medicinal product designation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Brochure/2011/03/WC500104234.pdf. Accessed December 9, 2013.
   Google Scholar
• Ferner RE, Hughes DA. The problem of orphan drugs. BMJ. 2010;341:c6456.
   Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–1783.
   PubMed Web of Science ®Google Scholar
• Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70:212–217.
   PubMed Web of Science ®Google Scholar
• Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671–673.
   PubMed Web of Science ®Google Scholar
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2:CD003279.
   Google Scholar